Literature DB >> 24607205

Galactosylated polymeric carriers for liver targeting of sorafenib.

Emanuela F Craparo1, Carla Sardo1, Rosa Serio2, Maria G Zizzo2, Maria L Bondì3, Gaetano Giammona4, Gennara Cavallaro5.   

Abstract

In this paper, we describe the preparation of liver-targeted polymeric micelles potentially able to carry sorafenib to hepatocytes for treatment of hepatocarcinoma (HCC), exploiting the presence of carbohydrate receptors, ASGPR. These micelles were prepared starting from a galactosylated polylactide-polyaminoacid conjugate. This latter was obtained by chemical reaction of α,β-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-d,l-aspartamide (PHEA-EDA) with polylactic acid (PLA), and subsequent reaction with lactose, leading to PHEA-EDA-PLA-GAL copolymer. Liver-targeted sorafenib-loaded micelles were obtained in aqueous media at low PHEA-EDA-PLA-GAL copolymer concentration value with nanometer size and slightly positive zeta potential. Biodistribution studies on mice demonstrated, after oral administration of sorafenib loaded PHEA-EDA-PLA-GAL micelles, the preferential sorafenib accumulation into the liver. This finding raises hope in terms of future drug delivery strategy of sorafenib-loaded micelles targeted to the liver for the HCC treatment.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active targeting; Galactosylation; Hepatic cell-targeted carriers; Polymeric micelles

Mesh:

Substances:

Year:  2014        PMID: 24607205     DOI: 10.1016/j.ijpharm.2014.02.047

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

Review 1.  Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.

Authors:  Sindisiwe Mvango; William M R Matshe; Abideen O Balogun; Lynne A Pilcher; Mohammed O Balogun
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

Review 2.  Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.

Authors:  Erika Dosekova; Jaroslav Filip; Tomas Bertok; Peter Both; Peter Kasak; Jan Tkac
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

3.  In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.

Authors:  Shaomei Yang; Bo Zhang; Xiaowei Gong; Tianqi Wang; Yongjun Liu; Na Zhang
Journal:  Int J Nanomedicine       Date:  2016-05-25

Review 4.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31

5.  Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma.

Authors:  Hea Ry Oh; Hyun-Young Jo; James S Park; Dong-Eun Kim; Je-Yoel Cho; Pyung-Hwan Kim; Keun-Sik Kim
Journal:  Nanomaterials (Basel)       Date:  2016-07-30       Impact factor: 5.076

6.  Effect of PEGylation on assembly morphology and cellular uptake of poly ethyleneimine-cholesterol conjugates for delivery of sorafenib tosylate in hepatocellular carcinoma.

Authors:  Maryam Monajati; Shirin Tavakoli; Samira Sadat Abolmaali; Gholamhossein Yousefi; AliMohammad Tamaddon
Journal:  Bioimpacts       Date:  2018-04-18

Review 7.  Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.

Authors:  Rossella Farra; Francesco Musiani; Francesca Perrone; Maja Čemažar; Urška Kamenšek; Federica Tonon; Michela Abrami; Aleš Ručigaj; Mario Grassi; Gabriele Pozzato; Deborah Bonazza; Fabrizio Zanconati; Giancarlo Forte; Maguie El Boustani; Lucia Scarabel; Marica Garziera; Concetta Russo Spena; Lucia De Stefano; Barbara Salis; Giuseppe Toffoli; Flavio Rizzolio; Gabriele Grassi; Barbara Dapas
Journal:  Molecules       Date:  2018-03-28       Impact factor: 4.411

8.  SPIO-loaded nanostructured lipid carriers as liver-targeted molecular T2-weighted MRI contrast agent.

Authors:  Xiuliang Zhu; Xueying Deng; Chenying Lu; Ying Chen; Liyong Jie; Qian Zhang; Wei Li; Zuhua Wang; Yongzhong Du; Risheng Yu
Journal:  Quant Imaging Med Surg       Date:  2018-09

9.  Pluronic® P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells.

Authors:  Diogo Silva Pellosi; Francesca Moret; Aurore Fraix; Nino Marino; Sara Maiolino; Elisa Gaio; Noboru Hioka; Elena Reddi; Salvatore Sortino; Fabiana Quaglia
Journal:  Int J Nanomedicine       Date:  2016-09-06

10.  Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma.

Authors:  Anne Clavreul; Emilie Roger; Milad Pourbaghi-Masouleh; Laurent Lemaire; Clément Tétaud; Philippe Menei
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.